ZIOPHARM Oncology, Inc. Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at American Association for Cancer Research Centennial Conference

MONTEREY, Calif.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company’s novel, orally administered, synthetic tubulin targeted agent, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine held in Monterey, California, July 20 to 23, 2008.